ZA200710952B - Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors - Google Patents

Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors

Info

Publication number
ZA200710952B
ZA200710952B ZA200710952A ZA200710952A ZA200710952B ZA 200710952 B ZA200710952 B ZA 200710952B ZA 200710952 A ZA200710952 A ZA 200710952A ZA 200710952 A ZA200710952 A ZA 200710952A ZA 200710952 B ZA200710952 B ZA 200710952B
Authority
ZA
South Africa
Prior art keywords
cyclohexylamin
rho
kinase inhibitors
isoquinolone derivatives
isoquinolone
Prior art date
Application number
ZA200710952A
Other languages
English (en)
Inventor
Plettenburg Oliver
Hofmeister Armin
Kadereit Dieter
Brendel Joachim
Loehn Matthias
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200710952B publication Critical patent/ZA200710952B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
ZA200710952A 2005-07-26 2007-12-18 Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors ZA200710952B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05016153 2005-07-26

Publications (1)

Publication Number Publication Date
ZA200710952B true ZA200710952B (en) 2008-11-26

Family

ID=35115842

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710952A ZA200710952B (en) 2005-07-26 2007-12-18 Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors

Country Status (37)

Country Link
US (2) US8609691B2 (xx)
EP (1) EP1912949B1 (xx)
JP (1) JP5049970B2 (xx)
KR (1) KR101336678B1 (xx)
CN (1) CN101228132B (xx)
AR (1) AR057082A1 (xx)
AT (1) ATE521595T1 (xx)
AU (1) AU2006274246B2 (xx)
BR (1) BRPI0614063A2 (xx)
CA (1) CA2615663C (xx)
CR (1) CR9604A (xx)
CY (1) CY1112085T1 (xx)
DK (1) DK1912949T3 (xx)
DO (1) DOP2006000177A (xx)
EC (1) ECSP088136A (xx)
ES (1) ES2372067T3 (xx)
GT (1) GT200600327A (xx)
HK (1) HK1123036A1 (xx)
HN (1) HN2008000130A (xx)
HR (1) HRP20110839T1 (xx)
IL (1) IL188949A (xx)
MA (1) MA29639B1 (xx)
MX (1) MX2008000956A (xx)
MY (1) MY146644A (xx)
NI (1) NI200800024A (xx)
NO (1) NO20080965L (xx)
NZ (1) NZ565669A (xx)
PE (1) PE20070181A1 (xx)
PL (1) PL1912949T3 (xx)
PT (1) PT1912949E (xx)
RS (1) RS52241B (xx)
RU (1) RU2440988C2 (xx)
SI (1) SI1912949T1 (xx)
TN (1) TNSN08038A1 (xx)
TW (1) TWI412521B (xx)
WO (1) WO2007012422A1 (xx)
ZA (1) ZA200710952B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441641T1 (de) 2005-06-28 2009-09-15 Sanofi Aventis Isochinolinderivate als inhibitoren von rho- kinase
NI200800024A (es) 2005-07-26 2009-03-03 Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa
BRPI0613861B8 (pt) 2005-07-26 2021-05-25 Sanofi Aventis derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CN101528703B (zh) * 2006-09-11 2011-09-07 欧加农股份有限公司 2-（1-氧代-1h-异喹啉-2-基）乙酰胺衍生物
DK2132194T3 (da) 2006-12-27 2011-06-27 Sanofi Aventis Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer
KR20090092303A (ko) * 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
CA2673918C (en) 2006-12-27 2015-02-17 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
CA2673917C (en) 2006-12-27 2015-01-27 Sanofi-Aventis Cycloalkylamine substituted isoquinolone derivatives
MX2009005825A (es) 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
DE602007010981D1 (de) 2006-12-27 2011-01-13 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
TW200845988A (en) 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
CN101910133A (zh) * 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
KR101638326B1 (ko) * 2008-06-24 2016-07-12 사노피 Ｒｈｏ 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논
PT2313374E (pt) * 2008-06-24 2013-11-29 Sanofi Sa Isoquinolinas e isoquinolinonas 6-substituídas
DK2303845T3 (da) 2008-06-24 2013-12-16 Sanofi Sa Bi- og polycyklisk substitueret isoquinolin og bi- og polycykliske substituerede isoquinolinderivater som rho-kinasehæmmere
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
BR112015017008A2 (pt) * 2013-01-18 2017-07-11 Bristol Myers Squibb Co ftalazinonas e isoquinolinonas como inibidores de rock
EP3057586B1 (en) 2013-10-18 2019-12-04 Celgene Quanticel Research, Inc. Bromodomain inhibitors
JP6307088B2 (ja) * 2013-10-23 2018-04-04 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US20180104692A1 (en) 2015-05-12 2018-04-19 Platod Combination of pharmacological and microfluidic features for improved platelets production
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017184462A1 (en) 2016-04-18 2017-10-26 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CN112839647A (zh) * 2018-06-07 2021-05-25 达萨玛治疗公司 Sarm1抑制剂
CN114874236B (zh) * 2022-06-24 2023-05-05 中国工程物理研究院化工材料研究所 一种五元氮杂稠环骨架及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja) 1990-07-31 1994-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 選択されたハロカーボンの触媒平衡化
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ATE359822T1 (de) 1996-08-12 2007-05-15 Mitsubishi Pharma Corp Medikamente enthaltend rho-kinase inhibitoren
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
WO1999011642A1 (en) 1997-08-29 1999-03-11 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
DE60119894D1 (de) 2000-01-20 2006-06-29 Eisai Co Ltd Piperidinverbindungen und diese enthaltenden medikamente
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
EP1351936A1 (en) 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
JPWO2004009555A1 (ja) * 2002-07-22 2005-11-17 旭化成ファーマ株式会社 ５−置換イソキノリン誘導体
KR20050019918A (ko) * 2002-07-22 2005-03-03 아사히 가세이 파마 가부시키가이샤 5-치환 이소퀴놀린 유도체
AU2003264427A1 (en) 2002-09-12 2004-04-30 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
WO2004080464A1 (en) * 2003-03-11 2004-09-23 Novartis Ag Use of isoquinoline derivatives for treating cancer and map kinase related diseases
US20040225116A1 (en) 2003-05-08 2004-11-11 Payne Mark S. Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1678623B1 (en) 2003-08-22 2008-10-22 4Links Limited Communication system using embedded synchronisation
CN1856476A (zh) 2003-09-23 2006-11-01 默克公司 异喹啉酮钾通道抑制剂
WO2005030130A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
JPWO2005035516A1 (ja) 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
JP4969049B2 (ja) * 2004-04-06 2012-07-04 株式会社アマダ 曲げ加工装置
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1741525A1 (de) 2005-07-06 2007-01-10 Trumpf Werkzeugmaschinen GmbH + Co. KG Vorrichtung zur Aufnahme von plattenförmigen Materialien
NI200800024A (es) 2005-07-26 2009-03-03 Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa
BRPI0613861B8 (pt) 2005-07-26 2021-05-25 Sanofi Aventis derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
JP4033221B2 (ja) 2005-12-02 2008-01-16 ダイキン工業株式会社 冷媒加熱装置
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
DK2132194T3 (da) 2006-12-27 2011-06-27 Sanofi Aventis Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer
DE602007010981D1 (de) 2006-12-27 2011-01-13 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate

Also Published As

Publication number Publication date
WO2007012422A1 (en) 2007-02-01
BRPI0614063A2 (pt) 2011-03-09
ES2372067T3 (es) 2012-01-13
TWI412521B (zh) 2013-10-21
DOP2006000177A (es) 2007-06-15
CA2615663A1 (en) 2007-02-01
TW200800906A (en) 2008-01-01
KR101336678B1 (ko) 2013-12-04
RS52241B (en) 2012-10-31
NO20080965L (no) 2008-02-22
SI1912949T1 (sl) 2011-12-30
IL188949A0 (en) 2008-04-13
DK1912949T3 (da) 2011-11-28
CN101228132B (zh) 2012-10-10
AU2006274246A1 (en) 2007-02-01
CY1112085T1 (el) 2015-11-04
RU2008106926A (ru) 2009-09-10
CA2615663C (en) 2013-10-15
ATE521595T1 (de) 2011-09-15
US20080242699A1 (en) 2008-10-02
AR057082A1 (es) 2007-11-14
IL188949A (en) 2013-11-28
MY146644A (en) 2012-09-14
MX2008000956A (es) 2008-03-27
HN2008000130A (es) 2010-12-27
CR9604A (es) 2008-04-10
PL1912949T3 (pl) 2012-01-31
GT200600327A (es) 2007-02-05
EP1912949B1 (en) 2011-08-24
MA29639B1 (fr) 2008-07-01
HRP20110839T1 (hr) 2011-12-31
JP2009502830A (ja) 2009-01-29
US8609691B2 (en) 2013-12-17
RU2440988C2 (ru) 2012-01-27
ECSP088136A (es) 2008-02-20
CN101228132A (zh) 2008-07-23
EP1912949A1 (en) 2008-04-23
NZ565669A (en) 2010-05-28
PT1912949E (pt) 2011-11-23
JP5049970B2 (ja) 2012-10-17
KR20080028970A (ko) 2008-04-02
PE20070181A1 (es) 2007-03-07
US20110251226A1 (en) 2011-10-13
US8796458B2 (en) 2014-08-05
AU2006274246B2 (en) 2012-07-12
NI200800024A (es) 2009-03-03
HK1123036A1 (en) 2009-06-05
TNSN08038A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
HK1123035A1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
HK1123036A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
ZA200710001B (en) Isoquinoline derivatives as inhibitors or Rho-kinase
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
HK1139390A1 (en) Cycloalkylamine substituted isoquinolone derivatives
HK1105592A1 (en) Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
ZA200903554B (en) Substituted isoquinolines and their use as rho-kinase inhibitors
HK1124068A1 (en) 2-arylindole derivatives as mpges-1 inhibitors
EP1829864A4 (en) ISOCHINOLINE DERIVATIVES AS CALPAININHIBITORS
HK1112918A1 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200801910B (en) Isoquinolines derivatives as IGF-IR inhibitors
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors